Table 2.
Plasma adrenocorticotropic hormone (ACTH) concentrations in Group A and Group B after switching from conventional hydrocortisone treatment (IR-HC) to dual-release hydrocortisone (DR-HC) in fractionated doses.
| GROUP A | GROUP B | P-value (DR-HC Group A vs Group B) | ||||
|---|---|---|---|---|---|---|
| ACTH IR-HC (pg/ml) | ACTH DR-HC(pg/ml) | ACTH IR-HC (pg/ml) | ACTH DR-HC (pg/ml) | |||
| Patient 1 | 445 | 274 | Patient 1 | 931 | 830 | |
| Patient 2 | 480 | 137 | Patient 2 | 831 | 627 | |
| Patient 3 | 310 | 163 | Patient 3 | 539 | 476 | |
| Patient 4 | 265 | 120 | Patient 4 | 1,058 | 810 | |
| Patient 5 | 379 | 174 | Patient 5 | 990 | 686 | |
| Patient 6 | 445 | 263 | Patient 6 | 870 | 469 | |
| Patient 7 | 341 | 172 | Patient 7 | 638 | 486 | |
| Patient 8 | 415 | 169 | Patient 8 | 860 | 678 | |
| Patient 9 | 492 | 178 | Patient 9 | 745 | 580 | |
| Patient 10 | 530 | 168 | Patient 10 | 662 | 594 | |
| Median | 430 (333–483) | 171 (163–178) | Median | 845 (656–945) | 611 (486–686) | 0.0002 |
At 6 months of follow-up after switching from conventional hydrocortisone treatment (IR-HC) to dual-release hydrocortisone (DR-HC) we compared ACTH levels in the two groups. Group A patients showed significant lower levels of ACTH compared to Group B patients [Group A vs Group B, ACTH: 171 pg/ml (163–178) vs 611 pg/ml (486–686), p = 0.0002.